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ABSTRACT
Background: Multiple sclerosis (MS) risk is determined by both
genesandenvironment.OneofthemoststrikingfeaturesofMSisits
geographic distribution, particularly the pattern of high MS fre-
quency in areas with low sunlight exposure, the main inducer of
vitamin D synthesis. Recent epidemiologic, experimental, and clin-
ical evidence support an effect for low environmental supplies of
vitamin D in mediating an increased susceptibility to MS.
Objectives: We 1) examined the association of serum 25-hydroxy-
vitaminD [25(OH)D] concentrations and MS status and 2) assessed
the genetic contribution to serum 25(OH)D concentrations and
tested for its association with genetic variants in 2 candidate genes
[vitamin D receptor and 1--hydroxylase (CYP27B1)].
Design: We used a twin study approach, comprising adult pairs
identifiedfromthelongitudinalpopulation-basedCanadianCollab-
orativeProjectonGeneticSusceptibilitytoMS.Monozygotic(MZ;
n  40) and dizygotic (DZ; n  59) pairs, both concordant and
discordant for MS, were studied. End-of-winter serum 25(OH)D
concentrations were measured by radioimmunoassay, and geno-
types were assessed by single nucleotide polymorphism (SNP) as-
say.
Results: Serum concentrations of 25(OH)D were highly correlated
in MS-concordant pairs (r  0.83, P  0.001), but they were not
significantly associated with having the disease (P  0.4) when
analyzed by logistic regression. Intraclass correlation for 25(OH)D
concentration was significantly greater in MZ pairs (MZ, r: 0.71 
DZr:0.32,P0.006).Significantassociationsof2CYP27B1SNP
variants and 25(OH)D concentrations were observed.
Conclusion: The findings indicate important genetic influences on
regulation of seasonal circulating 25(OH)D concentrations in MS
twins. Am J Clin Nutr 2008;88:441–7.
INTRODUCTION
Thecauseofmultiplesclerosis(MS)isunknown,butitiswidely
accepted as a complex trait that develops in genetically susceptible
persons exposed to as yet undefined environmental risk factors (1).
Thestrongest,consistentlyreplicated,geneticsusceptibilityfactoris
the major histocompatibility complex human leukocyte antigen–
dicloro-1--D-ribofuranosyl-benzimidazole 1 (HLA-DRB1) locus
(1). The environmental component in MS susceptibility has at-
tracted relatively little study in the past few decades. Genetic
epidemiologic evidence strongly indicates that environment or
gene-environment interactions in MS risk act at a broad popula-
tion level (2–5). The most striking feature of MS epidemiology
haslongbeenthegeographicaldistributionofprevalence(6),and
its determinants are thought to be central to the environmental
componentsinMSrisk.ThegradientofincreasingMSriskwith
increasinglatitudeinbothhemispheresiscoincidentwithannual
sunlight exposure and frequency of vitamin D deficiency (7).
Several decades ago it was proposed that vitamin D adequacy
mediates this ultraviolet radiation (UVR)–latitude effect (8). In-
adequate concentrations of vitamin D has since reemerged as a
prime candidate in MS susceptibility and pathogenesis (9), al-
though strong evidence directly supporting this hypothesis has
been difficult to establish (10).
Clinical observations include low serum concentrations of
25-hydroxyvitamin D [25(OH)D] in MS patients (11, 12), sea-
sonal fluctuation in the timing of MS births (13, 14), and fluctu-
ation in MS disease activity correlating with 25(OH)D season-
ality (15, 16). Vitamin supplementation (17) and high
concentrations of serum 25(OH)D in adulthood (18) were mod-
estly associated with reduced risk of MS in 2 US cohort studies.
In addition, sunlight exposure through outdoor activity has
shownaninversecorrelationwithMSrisk(19–22).Associations
ofvariousvitaminDreceptor(VDR)genevariantsandMSwere
also reported (23–25). In animal models for MS, prenatal hypo-
vitaminosisDinratshasshownimpairednervoussystemdevel-
opment (26), and 1,25-dihydroxy-vitamin D inhibits develop-
mentandprogressionofexperimentalallergicencephalomyelitis
(27).
25(OH)D is the main circulating metabolite of vitamin D and
is the best measure of vitamin D adequacy (28). Circulating
25(OH)Dconcentrationsarepredominantlyinfluencedbyultra-
violet B exposure from sunlight (9), although evidence suggests
that genetic factors are also important (29, 30). Presumably, any
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 genetic effect and elucidating genes involved would be most
evident when ultraviolet exposure is inadequate or seasonally
limited.ThisisthecaseinCanada,wheretheultravioletintensity
is inadequate for cutaneous vitamin D synthesis from approxi-
mately October to March (31, 32).
Maintainingoptimalconcentrationsofserum25(OH)Disim-
portant to immune health and disease risk (9, 10). However, the
relative contribution of genetic factors to maintaining 25(OH)D
adequacy is unclear, and published studies elucidating genes
involvedarescarce.Moresystematicstudiescouldshedlighton
underlying gene, gene-environment interactions, or both in-
volvedinMS.Theaimsofthisstudyweretoexaminethevitamin
D–MS relation and to investigate the genetic contribution to
circulating 25(OH)D.
SUBJECTS AND METHODS
Concentrationsofserum25(OH)Dwereassayedintwinpairs
concordant and discordant for MS. First, we examined the rela-
tionofdiseaseconcordanceto25(OH)Dconcentrations.Wenext
assessed the association of circulating 25(OH)D and MS affec-
tion status. Monozygotic (MZ) and dizygotic (DZ) pairs were
comparedtoexaminethegeneticinfluenceon25(OH)Dconcen-
trations. Finally, we tested for the association of candidate gene
polymorphismswithboth25(OH)Danddiseasestatus.25(OH)D
was the only vitamin D metabolite measured in this study; for
clarity, all references to vitamin D measurements within this
study implicate this particular metabolite.
Study group
Twin pairs were identified from the database of the longitu-
dinal, population-based Canadian Collaborative Project on the
Genetic Susceptibility to MS (CCPGSMS). The CCPGSMS as-
certainment, database, and consenting process were described
previously in detail (33). Procedures for recontact of the
CCPGSMS subjects were followed in accordance with the
study’s institutional review board guidelines. Two hundred
twenty persons participated by providing a blood sample and
completingashortquestionnaire(detailsbelow).Inclusioninthe
study required that both members of the twin pair agreed to
participate. The twin cohort within the CCPGSMS has been
followed for 20 y and has been described in detail (34). Zy-
gosity was determined by self-reporting, and accuracy was sub-
sequently verified in 10% of cases by microsatellite marker
genotyping.
Sampling
Given the large seasonal dependence of serum 25(OH)D con-
centrations, all blood was drawn at the end of winter (March or
April 2005) to minimize bias from environmental influence.
Serumwasextractedfromthesamplesandstoredat80 °C.The
study sample comprised 40 MZ and 59 DZ pairs, 18 of which
were concordant for MS. The mean age of the sample was 53 y
(range: 34–78 y), with an overall female-to-male sex ratio of
2.2:1. These characteristics are consistent with those of the
entire CCPGSMS twin cohort previously reported (34).
To limit potential confounders, a short interview-based ques-
tionnaire about factors known to significantly affect 25(OH)D
(9,35)wasadministeredbythehealthcareprofessionaldoingthe
venipuncture. The participants were asked whether they were
taking vitamin D supplements, had used a tanning bed, or had
taken a sunshine vacation within the previous 6 wk. Exclusion
criteriaincludedtakingsupplements800IU/d,useofatanning
bed, or vacation below the 38°N latitude within 6 wk before
blood collection. If a participant met any of those criteria, their
co-twin was also excluded.
Serum 25(OH)D assays
Radioimmunoassay was used to measure serum 25(OH)D.
Serum samples frozen at 80 °C were measured with commer-
cial immunoradiometric assay kits (DiaSorin Inc, Stillwater,
MN)thatdetect25(OH)D2and25(OH)D3equally.Radioimmu-
noassay kit instructions were followed as outlined previously
(36), and the antibody tracer was quantified with the use of a
gamma counter (RIASTAR; Canberra Packard, Mississauga,
Canada).TheintraassayandinterassayCVsaretypically16%;
a within-run CV was 10%. Results consistently report within
thecentral1SDofthemethodgroupmeanintheinternational
ExternalQualityAssuranceSurvey(EQAS,NorthwestThames,
United Kingdom).
Samples collected from all 220 twins were assayed for
25(OH)D concentration, but only 99 pairs met criteria for inclu-
sion in the statistical analyses. Twenty-two persons were ex-
cludedbecauseeithertheco-twinwasunavailable(n8)ortheir
answers to the interview questionnaire met exclusion criteria (n
14).Themeanconcentrationofserum25(OH)Dinthesubjects
excluded, based on questionnaire responses, was 167.1  5.4
nmol/L.
Genotyping
DNA was extracted from blood as outlined in previous
CCPGSMS studies (37). HLA-DRB1 types determined by mi-
crosatellite marker genotyping were available from past studies
(34).Thegenotypeswereusedforstratificationinanalysesbythe
presence or absence of HLA-DRB1*15, given the known in-
creased risk the alleles carry (37). In addition, 35 single nucleo-
tide polymorphisms (SNPs) from 2 candidate genes [VDR and
1--hydroxylase (CYP27B1)] were assayed on the Sequenom
MassARRAY platform (Sequenom, San Diego, CA). Genotyp-
ing was limited to 150 twins for whom DNA was available. To
ensurefullgenecoverage,theSNPpanelsforVDRandCYP27B1
wereselectedwiththeuseofHaploview(38)andweredesigned
to capture a minimum of 95% of all genetic variants listed in the
National Center for Biotechnology Information Entrez SNP and
Hapmap (Build 16) databases. Three variants failed the assay,
andanySNPwithtotalgenotypecounts10intheheterozygous
and rare homozygous groups combined (n  9) was excluded
from further analysis. The genotypes were analyzed for signifi-
cant effects on prediction of MS susceptibility, 25(OH)D con-
centrations, or both.
Statistical analysis
25(OH)D concentrations are reported as mean  SEM. For
regression analysis, values were log-transformed to generate an
approximate Gaussian distribution. Log 25(OH)D concentra-
tions were tested for prediction of MS status with the use of
logistic regression in STATA (39). Conversely, MS affection
statuswastestedfortheassociationwith25(OH)Dconcentration
with linear regression in STATA (39). Age and sex were incor-
porated as covariates, because they are thought to be factors in
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 both MS risk and vitamin D metabolism. For all models, adjust-
ment for the correlation between twin pairs was made with the
use of Huber-White robust variance estimation (40).
In the region flanking a causal variant, it is not uncommon to
seeseveralSNPsassociatedwithdisease.Thismaybearesultof
linkage disequilibrium of all SNPs tested with a single causal
variant, or it may be indicative of multiple causal variants. To
distinguishbetweenthesepossibilities,wecarriedoutmultilocus
modeling with the use of a forward selection approach. We first
assessed each SNP individually for association with log serum
25(OH)D concentrations, after adjustment for age, sex, and MS
status. We next tested whether the genetic variants were predic-
torsofMSaffectionstatus,afteradjustmentforage,sex,andlog
25(OH)Dconcentrations.Multilocusmodelsofassociationfully
take account of the underlying linkage disequilibrium between
SNPs, as well as the correlation in the effects of the SNPs; thus,
it may be more powerful to detect the association than single-
locus tests. All SNPs with single-locus effects of P  0.05 were
considered as potential predictors in an overall linear or logistic
regression model to test each SNP for independent effects of
significant association. At each stage, the most significantly as-
sociated SNP, after adjustment for the effects of all others in the
model, is included. To allow for multiple testing (24 SNPs), we
report results for a Bonferroni-corrected P value of 0.002.
RESULTS
Characteristics of twin data set
Analyses included 198 twin persons (130 women, 68 men)
withamean(SD)ageof53.19y.Thiscomprised40MZand
59 DZ pairs, of which 16 pairs were concordant for MS (11 MZ,
5 DZ). The overall mean (SEM) 25(OH)D concentration was
78.22.4nmol/L,andnosignificantdifferenceswereobserved
inthemeanconcentrationsofmencomparedwithwomenorMZ
twins compared with DZ twins (Table 1). Among all pairs dis-
cordantforMS,themean25(OH)Dconcentrationwassimilarin
affected and unaffected subjects (Table 1). Several subjects
(20.2%)hadconcentrationsintheinsufficiencyrange,definedas
45 nmol/L (31), 6 of which were 25 nmol/L. Rates of hypo-
vitaminosis were not significantly influenced by disease status,
MS concordance, sex, or age (data not shown).
25(OH)D concentrations and disease risk
Descriptively,itcanbeseenthat25(OH)Dconcentrationsare
moresimilarinMS-concordantpairs,butthismaybeaffectedby
zygosity (Table 1; Figure 1). The intrapair difference is simply
the absolute value of the difference between 25(OH)D concen-
tration in twin 1 and twin 2. MS-concordant pairs were highly
correlated for 25(OH)D concentrations (concordant pairs: r 
0.83, P  0.001; discordant pairs: r  0.37, P  0.01; Table 1).
ThemostdissimilargroupwastheDZ-discordantpairs(intrapair
difference: 33.2 nmol/L; correlation: r  0.28, P  0.380),
whereas MZ-concordant pairs were the most similar (intrapair
difference: 20.4 nmol/L; r  0.86, P  0.001). The intrapair
difference of same-sex compared with opposite-sex pairs was
similar (26.6 and 28.3 nmol/L, respectively).
To test for any significant trends of lower or higher 25(OH)D
concentrations in affected subjects, we used logistic regression,
afteradjustmentforageandsex.25(OH)Dconcentrationwasnot
a significant predictor of MS status in our sample (P  0.43;
Table 2). Stratification for the presence or absence of the HLA-
DRB1*15 risk alleles did not influence these results (Table 2).
Conversely, we examined whether MS status predicted
25(OH)D concentrations, and, again, no significant trends were
observed (data not shown). Overall, although disease-
concordantpairsweresignificantlycorrelatedfor25(OH)Dcon-
centrations, this did not appear to be a result of low or high adult
concentrations affecting the likelihood of MS affection status or
vice versa.
Genetic contribution to 25(OH)D concentration
Themeanintrapairdifferencefor25(OH)Dconcentrationwas
lower in MZ twin pairs than in DZ twin pairs (Table 1). We
assessedthesignificanceofthisintrapairvariationwiththeuseof
correlation statistics and regression models. Comparison of MZ
and DZ correlation coefficients for 25(OH)D concentrations
showedhighersimilarityinMZtwins(r0.71,P0.001)than
in DZ twins (r  0.32, P  0.014; Figure 1). The difference
between these MZ-DZ correlation values was significant (P 
0.006). Both discordant and concordant pairs were included in
thezygositycorrelation.Theheritabilityestimateforcirculating
25(OH)D was calculated [2  (rMZ  rDZ)], providing an
estimate of 0.77. Finally, the assessment of the HLA-DRB1*15
genotypeinthetwinsshowedassociation(asexpected)withMS
(odds ratio: 1.63, P  0.01) but not with concentrations of
25(OH)D (Table 3).
Genetic polymorphisms
Thirty SNPs of the VDR gene and 6 SNPs of the CYP27B1
gene were genotyped in the 150 subjects for whom DNA was
TABLE 1
Characteristics of the twin data set with respect to 25-hydroxyvitamin D 25(OH)D concentrations
Subjects 25(OH)D Intrapair difference of 25(OH)D
1 Intraclass correlation (r) P
2
n nmol/L nmol/L
All twins 198 78.2  2.4
3 27.8  3.3 —
Females 130 79.6  3.1 — —
Males 68 75.4  3.6 — —
Affected-discordant 83 75.5  3.6 — —
Unaffected-discordant 83 75.3  3.5 — —
Concordant 32 79.9  6.3 24.2  4.1 0.83 0.001
Discordant 166 75.4  2.5 27.9  3.8 0.37 0.010
1 Absolute value of the difference between 25(OH)D of twin 1 and twin 2 for each pair.
2 Significant correlation value.
3 x   SEM (all such values).
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 available. Multilocus modeling with the use of a forward selec-
tionapproachwasused.WefirstassessedeachSNPindividually
for association with log serum 25(OH)D concentrations, after
adjustment for age, sex, and MS status (Table 3). These covari-
ateswerenotsignificantpredictorsof25(OH)Dconcentration(P
 0.05); thus, they were dropped from the model. Next, we
similarly tested whether the genetic variants were predictors of
MS affection status, after adjustment for age, sex, and log
25(OH)D concentrations (Table 3). All SNPs with single-locus
association of P  0.05 were considered as potential predictors
inthemultilocusmodel.Theseincluded2CYP27B1variantsand
3 VDR variants (Table 3). Results are not presented for the re-
maining 24 SNPs that showed no trend for association (uncor-
rected P  0.05).
A Bonferroni correction for multiple testing was used (P 
0.002) for the multilocus model. VDR SNPs (rs2254210,
rs98784) tested for the association with MS status did not reach
significance (P  0.025, P  0.137, respectively; data not
shown). The 2 CYP27B1 SNPs (rs4646536, rs703842) both re-
mained significant predictors of 25(OH)D concentrations (P 
0.001 for both; Table 3). Association of the FokI (rs10735810)
SNP and 25(OH)D fell slightly below significance (P  0.005;
Table 4). The mean concentration in subjects with the FokI
genotype(GG)codingfortheshorterlengthVDRwas64.65.6
nmol/L compared with 83.2  3.9 nmol/L in subjects with the
AAandAGgenotype(Table4).Meanconcentrationswerelower
in subjects homozygous for the less frequent C allele in the
CYP27B1 SNPs (Table 4).
DISCUSSION
The evidence is compelling that MS is a disease strongly
influenced by 	1 environmental factors in genetically suscepti-
ble persons (1). Evidence from the CCPGSMS studies of adopt-
ees (2), step-siblings (5), and half-siblings (3) indicates that the
environmental component of MS risk is ubiquitous and acts at a
broad population level, rather than within the shared family en-
vironment. A protective role for UVR exposure, mediated by
vitamin D, remains the most attractive explanation for the lati-
tude gradient of MS prevalence (6, 41). The active vitamin D
metabolite, 1,25(OH)2D, is a potent immunomodulator that is
important to immune function and development (42). It may be
the imbalance or impairment of its immunologic functions that
implicatesvitaminDinsufficiencyinthepathogenesisofMSand
otherautoimmunediseases(42,43).Chroniclowconcentrations,
seasonal fluctuation, or acute effects are all plausible, but it
remainslikelythatanunderlyinggeneticpredispositiontoMSis
required.
Recently,theevidenceinsupportoftheMS–vitaminDtheory
hasmounted.Thisevidenceincludesgenetic(23–25)andexper-
imental (26, 27) studies, observational case-control and cohort
studies(17,19–22,44),andclinicalevidence(18,45,46).There
arecurrentlynoclinicaltrialsofvitaminDinMSprevention,but
2 treatment trials showed promising findings on reduction of
exacerbation rates (47, 48). If MS susceptibility is associated
with 25(OH)D concentrations, preventative measures could be
FIGURE 1. Intraclass correlation of serum 25-hyrdroxy-vitaminD [25(OH)D] concentration (in nmol/L) in monozygotic (MZ) and dizygotic (DZ) twin
pairs. The Pearson correlation coefficients were r  0.71 (P  0.001) and r  0.32 (P  0.014) for MZ and DZ twins, respectively. The difference between
the2correlationvalueswassignificant(P0.006).Thedashedlinesrepresentthetheoreticalaxisforfullcorrelation(r1)of25(OH)Dconcentrationswithin
each twin pair.
TABLE 2
Test for association of log 25-hydroxyvitamin D 25(OH)D
concentrations and multiple sclerosis (MS) affection status, with
adjustment for age and sex (n  198) as determined by logistic
regression analysis and with stratification by the presence or absence
of 	1 DRB1*15 risk allele
MS status Odds ratio 95% CI P
25(OH)D 1.24 0.72, 2.13 0.432
Sex 1.55 0.93, 2.59 0.094
Age 0.99 0.97, 1.01 0.176
25(OH)D
1
DRB1*15-positive 1.50 0.70, 3.21 0.297
DRB1*15-negative 1.04 0.52, 2.09 0.907
1 Adjusted for sex and age.
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 implemented easily and cost-effectively (49), especially given
the known additional health benefits of vitamin D (9).
Despite numerous reports investigating the vitamin D–MS
relation, most evidence is indirect, with relatively few studies
measuring patients’ vitamin D concentrations. This may be in
part due to the challenge of studying environmental susceptibil-
ityfactorsinadult-onsetdiseases,especiallythoseforwhichrisk
isbelievedtobeacquiredearlyinlife,asissuggestedforMS(13,
50).Thetimingofapossible25(OH)DinfluenceonMSsuscep-
tibility is unclear (ie, gestation, childhood, cumulative effects).
Given that concentrations are to a certain extent heritable (30,
51), combined with behavioral consistencies, we reasoned that
adult 25(OH)D concentrations potentially reflect prediagnosis
concentrations, especially if certain persons are prone to insuf-
ficiency. Wintertime sampling was used to minimize current
environmental effects because UVR wavelength is not effective
for cutaneous vitamin D synthesis during the Canadian winter.
Furthermore, a short questionnaire was used to reduce bias re-
sulting from use of tanning beds, supplements, and sunshine
vacations.
Serum25(OH)DconcentrationswereanalyzedinCCPGSMS
twin subjects to examine the vitamin D–MS relation. We found
ahighercorrelationof25(OH)Dconcentrationsinpairsinwhich
both twins were affected. Presumably, this observation could be
aresultof25(OH)Dstatusinfluencingdiseaseriskand,thus,the
likelihood of concordance or conversely the disease affecting
25(OH)D concentrations. However, analysis of 25(OH)D and
MS status (and vice versa) showed no significant associations.
HLA-DRB1*15 stratification did not alter this result. Neverthe-
less,itshouldbenotedthattheywereadulttwinpairs;conclusive
determinationof25(OH)DrelationtoMSriskmayrequiresam-
plingmanyyearsbeforediseaseonsetorevensamplingofmoth-
ers during gestation.
Severalrecentcase-controlstudiesinFinland(45,52),Ireland
(53), and Australia (46) also reported no difference in adult
concentrations of 25(OH)D between MS-affected and MS-
unaffected persons. Other studies have observed lower circulat-
ing 25(OH)D in MS patients (11, 12). In addition, the mean
25(OH)D concentration observed in our study was higher than
previous findings (54, 55), albeit consistent with others (53, 56,
57). These conflicting findings may be a result of regional dif-
ferences,interassayvariation,orstudydesign,includingdisease
stage.Indeed,theAustralianstudyfoundthetrendforlikelihood
of 25(OH)D insufficiency only among MS patients with an Ex-
panded Disability Status Scale score  3 (46).
Because the correlation of 25(OH)D concentrations in con-
cordanttwinpairswasnotaresultofMSstatus,weexaminedthe
effectsofzygosityon25(OH)Dconcentrations.MZandDZtwin
comparisons can provide insight into the genetic influence on a
particular trait (58). The limitation of equal environmental shar-
ing in adult twins is acknowledged, and interpretation relies on
the assumptions that differences will be similar for MZ and DZ
twins and that environmental effect is minimized in the current
study. The correlation for 25(OH)D concentrations in MZ twins
TABLE 3
Single-locus regression analyses for association of vitamin D receptor(VDR) and 1--hydroxylase (CYP27B1) gene variants with log 25-hydroxyvitamin D
25(OH)D concentrations and multiple sclerosis (MS) affection status
1
SNP; marker
25(OH)D concentration MS status
Coefficient 95% CI P
2 Odds ratio 95% CI P
2
VDR
rs2254210; A/G 0.03 0.15, 0.20 0.742 1.78 1.04, 3.06 0.036
FokI rs10735810; A/G 0.24 0.40, 0.80 0.003 0.68 0.41, 1.15 0.152
rs98784; C/T 0.04 0.04, 0.17 0.596 1.53 1.01, 2.30 0.043
CYP27B1
1
rs4646536; C/T 0.17 0.03, 0.31 0.020 0.96 0.61, 1.49 0.854
rs703842; C/T 0.18 0.04, 0.33 0.015 0.47 0.56, 1.29 0.450
HLA DRB1
DRB1*15; positive 0.08 0.03, 0.20 0.136 1.63 1.12, 2.38 0.010
1 SNP, single nucleotide polymorphism; HLA-DRB1, human leukocyte antigen–dicloro-1--D-ribofuranosyl-benzimidazole 1 gene.
2 SNPs with associations that meet threshold for multilocus analysis (P  0.05, uncorrected).
TABLE 4
Multilocus regression modeling to test for independent single nucleotide polymorphism (SNP) effects on association with log 25-hydroxyvitamin D
25(OH)D concentration
1
SNP Coefficient 95% CI P
3
25(OH)D
2
AA AG GG CC CT TT
nmol/L
VDR, FokI 0.21 0.34, 0.06 0.005 100  9
4 80  46 4  6 ———
CYP27B1, rs4646536 0.90 1.20, 0.60 0.001 — — — 62  77 3  48 6  5
CYP27B1, rs703842 1.02 0.83, 1.21 0.001 — — — 59  77 4  48 6  5
1 SNP, single nucleotide polymorphism; VDR, vitamin D receptor gene; CYP27B1,1 - -hydroxylase gene.
2 For each genotype at the respective SNP locus.
3 After Bonferroni correction for multiple tests (n  24), the threshold for significance is P  0.002.
4 x   SEM (all such values).
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 wasmorethandoublethatinDZtwins,andthemagnitudeofthe
difference was significant. This suggests that gene or gene-
environment factors influence the trait.
Evidenceforgeneticcontributionto25(OH)Dconcentrations
was shown previously in an osteoarthritis twin cohort of mainly
women(30),andagenome-widelinkagescaninasthmafamilies
reported a heritability index of 0.80 (51). Heritability estimates
indicate the amount of phenotypic variance ascribed to genetic
factors in a given population (58). They should not be mistaken
as a genetic percentage and are both time- and population-
dependent. The higher heritability index in the asthma and MS
cohorts may be a reflection of 25(OH)D influence on disease
susceptibility, such that the genetic effects are easier detected
in these cohorts. Given these findings, we conducted a prelimi-
nary assessment of vitamin D–related gene region effects on
25(OH)D.AssociationwithMSstatuswasalsoassessedbecause
this was previously reported (23, 24, 59). After Bonferroni cor-
rection,positiveassociationswith25(OH)Dconcentrationswere
observed for 2 CYP27B1 SNPs. Effects of the VDR FokI variant
fellslightlybelowsignificance,althoughthetrendisinteresting,
given its genotype-based differences in functionality (60). The
resultant VDR isoforms differ structurally, and decreased activ-
itywasobservedinthelongerisoform(60).AlthoughCYP27B1
and VDR actions are downstream of circulating 25(OH)D,
causal variants could possibly alter their role in metabolic feed-
backloopsoreffectthespeedatwhich25(OH)Dismetabolized.
Speculationontheoverallimportanceofthesegenesislimitedby
the sample size, and the findings merit follow-up.
Perhaps because of dominating environmental influences,
there has been little investigation into the genes involved in
regulation of serum 25(OH)D concentrations. Research about
vitamin D genes is predominantly focused on SNP-disease as-
sociations, and most does not relate this to 25(OH)D or other
metabolite concentrations. It is unclear the number, type, and
interactions of genes that may be involved, although one quan-
titative trait locus scan has identified several regions of interest
(51). The importance of genes in maintaining vitamin D ade-
quacy is likely to be most significant in regions where UVR
exposure is limited or is seasonally limited. It may be that some
persons are genetically more susceptible to low 25(OH)D con-
centrations. There is widespread consensus that current recom-
mended daily intake guidelines for vitamin D are not sufficient
foroptimalimmunehealth(9,49).Abetterunderstandingofthe
genetic contribution to 25(OH)D concentrations may have im-
portant implications in the debate for changing such guidelines.
Despite numerous studies that consider an association be-
tween vitamin D and MS risk, surprisingly few have directly
measured serum concentrations of vitamin D [25(OH)D] in MS
patients. Although we did not find an association of adult
25(OH)DconcentrationsandMSstatusinthecurrentstudy,that
doesnotruleoutthepossibilitythatsucharelationexists.Itmay
be that assessing childhood or even maternal concentrations is
required to support or refute the vitamin D–MS theory, and the
challenges of this are obvious. The present results support a
significant genetic influence in determining serum 25(OH)D
concentration, and further investigation to decipher the genes
involvedinitsregulationismerited.Ifaparticulargeneticback-
ground alters 25(OH)D influence on immune function, these
genetic factors could in turn affect susceptibility to MS.
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